Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).

Participants needed: 5,000
Trial details
Phase: Phase 4Age: 40-75Biological sex: AllType: InterventionalSponsor: Jung-min AhnUpdated: Jul 1, 2026Locations: 32
Eligibility criteria

The subject must be aged between 40 and 75 years. [+8]

Individuals who have symptomatic coronary artery disease or heart failure. [+13]

Read more
Status: Not yet recruiting

Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers

The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.

Participants needed: 2,034
Trial details
Age: 19+Biological sex: AllType: InterventionalSponsor: Jung-min AhnUpdated: May 4, 2026Locations: 1
Eligibility criteria

Adult men and women aged 19 years or older [+2]

Cardiogenic shock within 48 hours prior to the procedure [+6]

Read more
Status: Recruiting

Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent

The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the "real world" daily practice as compared with the other drug-eluting stents.

Participants needed: 2,000
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: Jung-min AhnUpdated: Dec 29, 2025Locations: 23Duration: 5 Years
Eligibility criteria

Patients ≥ 19 years old [+2]

Patients with a mixture of other drug-eluting stents (DESs) [+2]

Read more